Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
18 evidence topics · 26 sources
Summary: target population
The FDA has agreed to review the new drug application for darovasertib in combination with crizotinib for patients with first-line HLA-A∗02:01-negative metastatic uveal melanoma under the Real-Time Oncology Review program, and the submission includes data from OptimUM-02 and OptimUM-01. OptimUM-02 enrolled adults 18 years and older with histologically or cytologically confirmed metastatic uveal melanoma that is HLA-A∗02:01 negative, no prior systemic therapy in the metastatic or advanced setting and no prior regional or liver-directed therapy (ablation or resection of oligometastatic disease and neoadjuvant or adjuvant therapy were allowed), measurable disease per RECIST 1.1, ECOG performance status 0 or 1, and a life expectancy of at least 3 months. Participants could be initially diagnosed with metastatic disease or have metastases after therapy for localized uveal melanoma. The trial excluded prior treatment with a PKC inhibitor or an inhibitor directly targeting MET, symptomatic or untreated CNS metastases, a high risk of syncope or falls, stroke within the last 6 months, and clinically significant cardiac disease. OptimUM-01 data, including the phase 2 expansion in 101 HLA-A∗02:01-positive participants, are intended to support discussions on expanding the labeled indication. Crizotinib is FDA approved for ALK- or ROS1-positive metastatic non-small cell lung cancer, ALK-positive anaplastic large cell lymphoma, and ALK-positive inflammatory myofibroblastic tumor. Identifying the population requires HLA-A∗02:01 typing, which a reference laboratory reports in 3 to 7 days; in a deidentified database of 219 patients, HLA-A∗02:01 status was negative in 42.9% and unknown in 15.1%.
Summary: position relative to current first-line therapy by HLA status and disease distribution
For HLA-A∗02:01-positive patients, tebentafusp is approved by the FDA and the EMA as first-line systemic treatment and is recommended as standard of care in the first-line metastatic setting unless liver-directed treatment is required first for tumour debulking. For HLA-A∗02:01-negative patients, in the absence of a standard of care, liver-directed therapies (PHP and IHP), anti-PD-1-based immunotherapies, and clinical trial enrolment are the preferred options; patients with extensive disease are encouraged to enter a clinical trial, with percutaneous hepatic perfusion or checkpoint inhibitors alone or in combination as alternatives, and local therapies are proposed for limited hepatic metastases. By disease distribution, oligometastatic disease confined to the liver can be considered for resection or thermal ablation, and multifocal metastases confined to the liver for regional perfusion.
Darovasertib plus crizotinib would enter first-line treatment of HLA-A∗02:01-negative disease. In 313 participants of the phase 2b/3 portion of OptimUM-02, the combination reduced the risk of progression by blinded independent central review by 58% (hazard ratio 0.42; 95% CI 0.30 to 0.59) compared with investigator's choice of pembrolizumab, ipilimumab plus nivolumab, or dacarbazine, with median progression-free survival of 6.9 versus 3.1 months. Dr. Lutzky stated that tebentafusp remains the preferred first-line therapy for HLA-A∗02:01-positive disease, that darovasertib plus crizotinib may become an alternative for selected patients with rapidly progressive disease, extensive liver involvement, or a need for prompt tumor shrinkage, and the same report states that darovasertib plus crizotinib “appears likely to become the preferred systemic first-line option”; percutaneous hepatic perfusion remains important for liver-dominant disease with preserved hepatic function. Faculty in an OncLive report did not support combining darovasertib plus crizotinib with tebentafusp upfront because of overlapping toxicity, or frontline dual checkpoint inhibition outside a clinical trial. The ESMO 2026 poster authors describe the combination as a potential “new oral standard of care” in this setting, and IDEAYA cites OptimUM-01 in support of its potential for patients irrespective of HLA-A∗02:01 status and line of therapy. The progression-free survival data may enable an accelerated approval filing, with overall survival from a prespecified interim analysis expected in mid-2027 to support full approval.
Summary: anticipated use and care setting
The combination is taken orally: participants received darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily, the recommended phase 2 dose, whereas the crizotinib label recommends 250 mg twice daily for NSCLC and lists 200 mg twice daily as its first dose reduction; crizotinib capsules are taken with or without food. The sponsor states that “A daily oral targeted regimen has the potential to improve compliance”. Tebentafusp, by comparison, requires weekly intravenous administration with observation at initiation, inpatient monitoring for the first 3 to 4 infusions in an experienced institution before subsequent infusions in a community clinic, and considerable pharmacy resources to prepare each dose.
Expert panelists noted that an oral regimen “removes the referral-forcing function that intravenous therapies create”, while the combination carries nausea, vomiting, diarrhea, and edema that low-volume community centers may not be able to manage; one panelist proposed a mandatory link to an expert center with community physicians managing maintenance. The short half-life of the combination typically makes brief holds and dose reductions, with dietary counseling, sufficient to keep patients on therapy, and the mean delivered dose intensity was 80% or more. Supportive measures for orthostatic hypotension during initial dosing include adequate hydration, initial withholding of blood pressure medications, and avoiding abrupt posture changes. The crizotinib label calls for liver function tests every 2 weeks during the first 2 months and then monthly, and ECG and electrolyte monitoring in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or QT-prolonging medications; OptimUM-02 excluded strong CYP3A4/5 inducers or inhibitors and narrow therapeutic index CYP3A4/5 substrates. A 2026 guideline recommends discussing therapeutic options at an oncology or molecular tumour board in reference centres with expertise in uveal melanoma, and a community oncology practice reports treating metastatic uveal melanoma in most of its clinic locations, a disease a general oncologist may see only once every several years. Darovasertib is currently available only through clinical trials; IDEAYA has initiated planning for potential commercial operations and expects a moderately sized specialty sales force to reach the relevant specialists, and Servier will be responsible for commercialization outside the U.S.
Darovasertib plus crizotinib in the targeted agents section of the guideline
“An interim analysis of a phase II trial ( NCT03947385 ) evaluating darovasertib in combination with the mesenchymal-epithelial transition factor (c-MET) inhibitor crizotinib showed ORR of 31% in the first 35 assessable patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp as the approved first-line systemic treatment for HLA-A∗02:01-positive disease
“In 2021, tebentafusp demonstrated OS benefit in the HLA-A∗02:01-positive first-line population; 23 the first time a systemic treatment showed a survival benefit in metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tebentafusp has been approved by the FDA and the European Medicines Agency (EMA) as first-line systemic treatment in HLA-A∗02:01-positive patients with metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sequencing by HLA-A∗02:01 status in the French expert consensus guidelines
“Systemic therapy with tebentafusp is the standard of care for HLA-A*02:01-positive patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For HLA-A*02:01-negative patients with extensive disease, treatment options are limited.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“They are encouraged to participate in a clinical trial, alternatively, percutaneous hepatic perfusion, ICI alone or in combination can be proposed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Local therapies are proposed for patients with limited hepatic metastases, from liver surgery to isolated hepatic perfusion and chemoembolisation for patients with more extensive hepatic involvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical trials for HLA-A∗02:01-negative patients and combination of tebentafusp with locoregional therapy in a 2026 review
“The first-line treatment for HLA-A*02:01-positive MUM patients of tebentafusp can be combined with locoregional therapies upfront or in case of oligoprogression on tebentafusp following multidisciplinary tumor board (MTB) discussion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HLA-A*02:01-negative MUM patients should be offered participation in clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Innovative drugs, such as DYP688 or the combination of darovasertib and crizotinib, are promising.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discussant view of first-line sequencing by HLA-A∗02:01 status after the OptimUM-02 presentation
Discussant statement that the question has shifted to sequencing
Expert workshop positions on darovasertib plus crizotinib, combination with tebentafusp, and first-line dual checkpoint inhibition
Oral administration, community management, and linkage to expert centers
Weekly intravenous tebentafusp with observation at initiation, as contrasted by the OptimUM-01 investigators
Inpatient and outpatient initiation of tebentafusp in practice
Treatment in community oncology practice and clinical pathways for a rare disease
Tumor board discussion in reference centers and access to expert centers
“Therapeutic options should be discussed at an oncology or molecular tumour board (MTB) in reference centres with expertise in UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MTB should at minimum include ophthalmologists (optionally), pathologists, interventional radiologists, liver surgeons, radiation and medical oncologists.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“National networks and patient advocacy groups may help facilitate patient access to expert centres and organise local patient care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote